Free Trial
NASDAQ:CVAC

CureVac (CVAC) Stock Price, News & Analysis

CureVac logo
$4.66 0.00 (0.00%)
As of 11/11/2026

About CureVac Stock (NASDAQ:CVAC)

Advanced

Key Stats

Today's Range
$4.66
▼
$4.66
50-Day Range
$4.66
▼
$4.66
52-Week Range
$3.13
▼
$5.72
Volume
N/A
Average Volume
992,546 shs
Market Capitalization
$1.05 billion
P/E Ratio
6.47
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

CureVac is a biotechnology company founded in 2000 and headquartered in Tübingen, Germany. It focuses on messenger RNA (mRNA) technology, which uses genetic instructions to prompt cells to produce proteins that may help prevent or treat disease.

The company has developed mRNA-based vaccine and therapeutic candidates for infectious diseases and cancer. Its programs have included COVID-19 vaccines and oncology research, and it has worked with pharmaceutical partners, including GSK, on mRNA vaccine development.

CureVac’s research and clinical development activities have a global scope, with collaborations and programs involving partners and research sites in multiple regions. Its work centers on advancing mRNA medicines from early research through clinical testing.

AI Generated. May Contain Errors.

Receive CVAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CVAC Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.
CureVac NV (CVAC): A bull case theory
See More Headlines

CVAC Stock Analysis - Frequently Asked Questions

CureVac's stock was trading at $4.52 at the beginning of the year. Since then, CVAC shares have increased by 3.1% and is now trading at $4.66.

CureVac N.V. (NASDAQ:CVAC) released its quarterly earnings results on Monday, November, 24th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.07. The company earned $63.53 million during the quarter, compared to analyst estimates of $21.40 million. CureVac had a negative trailing twelve-month return on equity of 23.03% and a net margin of 199.92%.

CureVac (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,333,333 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers.

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include Tesla (TSLA), Novavax (NVAX), Moderna (MRNA), NIO (NIO), BioNTech (BNTX), NVIDIA (NVDA) and Pfizer (PFE).

Company Calendar

Today
11/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CVAC
CIK
1809122
Employees
880
Year Founded
2000

Profitability

EPS (Trailing Twelve Months)
$0.72
Trailing P/E Ratio
6.47
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$175.50 million
Net Margins
199.92%
Pretax Margin
232.79%
Return on Equity
-23.03%
Return on Assets
-19.09%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
3.70
Quick Ratio
3.69

Sales & Book Value

Annual Sales
$70.74 million
Price / Sales
14.78
Cash Flow
$0.99 per share
Price / Cash Flow
4.73
Book Value
$3.36 per share
Price / Book
1.39

Miscellaneous

Outstanding Shares
224,338,000
Free Float
219,515,000
Market Cap
$1.05 billion
Optionable
No Data
Beta
1.77

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:CVAC) was last updated on 11/11/2026 by MarketBeat.com Staff.
From Our Partners